Back to News
Market Impact: 0.4
Contineum's Phase 2 MOONLIGHT-1 Trial Misses Primary Endpoint In MDD; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Contineum Therapeutics said its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 monotherapy in adults with major depressive disorder failed to achieve its primary efficacy endpoint. The result is a material clinical-development setback for the asset and could pressure Contineum shares and expectations for the program's future development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
CTNM-0.85
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Intel’s stock crashes, knocking $12B from government’s stake
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools